• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SLNO

    Soleno Therapeutics Inc.

    Subscribe to $SLNO
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: soleno.life

    Recent Analyst Ratings for Soleno Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    5/10/2024$72.00Outperform
    Robert W. Baird
    2/5/2024$93.00Overweight
    Piper Sandler
    1/23/2024$63.00Buy
    Stifel
    11/21/2023$40.00Buy
    Guggenheim
    See more ratings

    Soleno Therapeutics Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

      SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 12:02:12 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SCHEDULE 13G filed by Soleno Therapeutics Inc.

      SCHEDULE 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 10:45:26 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Soleno Therapeutics Inc.

      10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      5/7/25 4:13:45 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      5/7/25 4:06:27 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

      SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      4/30/25 5:15:20 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by Soleno Therapeutics Inc.

      DEFA14A - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      4/22/25 4:52:10 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Soleno Therapeutics Inc.

      DEF 14A - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      4/22/25 4:49:11 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 8-K filed by Soleno Therapeutics Inc.

      8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      4/18/25 5:10:56 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Soleno Therapeutics Inc.

      144 - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      4/1/25 4:16:41 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Soleno Therapeutics Inc.

      144 - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      3/28/25 4:09:20 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). "The validation of our MAA represents the next significant milestone in our mission to deliver this important therapy to the broad PWS communit

      5/22/25 5:32:41 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Participate in Upcoming June Conferences

      REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June: Jefferies Global Healthcare ConferencePresentation Date: Wednesday, June 4, 2025 at 10:30 AM ETPresentation Format: Corporate PresentationWebcast: Here Goldman Sachs 46th Healthcare ConferencePresentation Date: Tuesday, June 10, 2025 at 8:40 AM ETPresentation Format: Corporate PresentationWebcast: Here A replay of both events will be available in the Investors section on the Company's website at www.sol

      5/21/25 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms. "We

      5/20/25 4:05:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025

      REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced poster presentations from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated PWS at the Pediatric Endocrine Society (PES) Meeting 2025, which is being held May 15-18, in National Harbor, Maryland. Details of the presentations are as follows: PES 2025 Title: Long-term administration of diazoxide choline extended-release (DCCR) tablets in people with Prader-Will

      5/15/25 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden of Prader-Willi syndrome (PWS) and findings from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia associated PWS at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting 2025, which is being held May 13-16, in Montreal, Canada.    Details of the presentations are as follows: ISPOR 2025  Title: Expec

      5/13/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

      REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment of hyperphagia associated with Prader-Willi syndrome (PWS) at the Joint Congress of European Society for Pediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) Meeting 2025, which is being held May 10-13, 2025, in Copenhagen, Denmark. VYKAT XR was approved by the U.S. Food and Drug Admi

      5/8/25 4:05:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

      5/7/25 4:01:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

      REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, May 7, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferenc

      4/23/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces VYKAT(TM) XR Launch

      REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. "We are extremely pleased to begin delivering VYKAT XR,

      4/14/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

      First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. begin

      3/26/25 5:15:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/19/24 9:44:27 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 4:30:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 12:51:18 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Soleno Therapeutics Inc.

      SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 9:36:40 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/12/24 9:33:08 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Soleno Therapeutics Inc.

      SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      10/3/24 9:55:36 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Soleno Therapeutics Inc.

      SC 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      9/5/24 6:37:11 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Soleno Therapeutics Inc. (Amendment)

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/1/24 1:07:46 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Soleno Therapeutics Inc. (Amendment)

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      2/14/24 4:51:40 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Soleno Therapeutics Inc. (Amendment)

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      2/14/24 4:05:37 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Soleno Therapeutics Set to Join Russell 3000® Index

      REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

      6/4/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Strengthens Leadership Team with Key Appointments

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

      1/24/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

      REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

      8/16/23 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel resumed coverage on Soleno Therapeutics with a new price target

      Stifel resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      3/5/25 7:44:16 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stifel reiterated coverage on Soleno Therapeutics with a new price target

      Stifel reiterated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      12/2/24 10:10:09 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Robert W. Baird reiterated coverage on Soleno Therapeutics with a new price target

      Robert W. Baird reiterated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

      12/2/24 8:19:44 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • H.C. Wainwright initiated coverage on Soleno Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $70.00

      9/3/24 7:56:43 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Robert W. Baird initiated coverage on Soleno Therapeutics with a new price target

      Robert W. Baird initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

      5/10/24 7:49:57 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Piper Sandler initiated coverage on Soleno Therapeutics with a new price target

      Piper Sandler initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $93.00

      2/5/24 6:40:16 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stifel initiated coverage on Soleno Therapeutics with a new price target

      Stifel initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $63.00

      1/23/24 8:10:35 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Guggenheim resumed coverage on Soleno Therapeutics with a new price target

      Guggenheim resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $40.00

      11/21/23 7:46:31 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer resumed coverage on Soleno Therapeutics with a new price target

      Oppenheimer resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $8.00

      3/4/21 12:10:54 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

      5/7/25 4:01:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

      REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, May 7, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferenc

      4/23/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

      First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. begin

      3/26/25 5:15:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

      Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024 Company to Host Conference Call and Webcast Today at 9:00 AM ET REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- September 26, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Di

      9/26/23 7:30:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Hirano Patricia C sold $265,156 worth of shares (3,782 units at $70.11), decreasing direct ownership by 12% to 27,036 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      4/2/25 5:38:26 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Pauls Matthew exercised 5,937 shares at a strike of $4.60 and sold $424,797 worth of shares (5,937 units at $71.55) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:24:33 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Officer Yen Kristen sold $6,376,789 worth of shares (95,500 units at $66.77) and exercised 40,638 shares at a strike of $4.97, decreasing direct ownership by 66% to 28,143 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:23:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Commercial Officer Manning Meredith sold $3,044,343 worth of shares (45,249 units at $67.28) and exercised 37,000 shares at a strike of $46.31, decreasing direct ownership by 15% to 45,351 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:21:03 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHIEF FINANCIAL OFFICER Mackaness James H sold $6,293,177 worth of shares (90,622 units at $69.44) and exercised 70,000 shares at a strike of $11.72, decreasing direct ownership by 16% to 105,176 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:20:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Sr. VP of Clinical Development Huang Michael F. sold $1,013,627 worth of shares (14,583 units at $69.51) and exercised 10,000 shares at a strike of $21.93, decreasing direct ownership by 11% to 36,817 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:18:50 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Officer Hirano Patricia C sold $10,709,353 worth of shares (156,315 units at $68.51) and exercised 74,831 shares at a strike of $8.14, decreasing direct ownership by 73% to 30,818 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:01:24 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHIEF EXECUTIVE OFFICER Anish Bhatnagar sold $47,271,960 worth of shares (699,095 units at $67.62) and exercised 523,809 shares at a strike of $12.17, decreasing direct ownership by 23% to 577,076 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:00:18 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Vivo Opportunity, Llc sold $124,449,124 worth of shares (1,833,557 units at $67.87) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/28/25 7:03:30 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Officer Yen Kristen was granted 6,400 shares, increasing direct ownership by 8% to 83,005 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      1/23/25 4:29:19 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Soleno Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      9/28/23 3:45:22 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care